混合闭环与手动胰岛素输注在成人1型糖尿病中的随机对照试验
HCL组TIR从55%升至70%,对照组不变,组间差异15%(95%CI 11-19,P<0.0001),HbA1c中位差异-0.4%(P<0.0001),糖尿病特异性积极幸福感更高。
要点
- HCL较手动治疗显著改善TIR(差异15%,P<0.0001)。
- HCL组HbA1c中位降低0.4%(P<0.0001)。
- HCL组糖尿病特异性积极幸福感更高(差异1.2,P=0.0048)。
核心结论
- 在成人1型糖尿病患者中,26周HCL较继续手动胰岛素输注和指尖血糖监测改善了TIR、HbA1c和糖尿病管理满意度。
- 试验表明HCL对全球大多数1型糖尿病患者可行、可接受且具有优势。
研究设计与样本
- 随机对照试验,成人1型糖尿病使用MDI或胰岛素泵且未使用CGM者随机分配至26周HCL(Medtronic 670G)或继续当前治疗。
- HCL组61例,对照组59例;基线平均年龄44.2岁,HbA1c 7.4%,女性53%,使用MDI者51%。
主要发现
- HCL组TIR从基线55%增至26周70%,对照组从55%至55%,组间差异15%(95%CI 11,19;P<0.0001)。
- HCL组HbA1c中位差异-0.4%(95%CI -0.6,-0.2;-4 mmol/mol,95%CI -7,-2;P<0.0001)。
- HCL组糖尿病特异性积极幸福感更高(差异1.2,95%CI 0.4,1.9;P<0.0048),糖尿病痛苦、感知睡眠质量或认知无恶化。
临床怎么用
- 对于使用MDI或胰岛素泵但未使用CGM的成人1型糖尿病患者,可考虑HCL以改善血糖控制和糖尿病管理满意度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate glycemic and psychosocial outcomes with hybrid closed-loop (HCL) versus user-determined insulin dosing with multiple daily injections (MDI) or insulin pump (i.e., standard therapy for most adults with type 1 diabetes). RESEARCH DESIGN AND METHODS: Adults with type 1 diabetes using MDI or insulin pump without continuous glucose monitoring (CGM) were randomized to 26 weeks of HCL (Medtronic 670G) or continuation of current therapy. The primary outcome was masked CGM time in range (TIR; 70-180 mg/dL) during the final 3 weeks. RESULTS: Participants were randomized to HCL (n = 61) or control (n = 59). Baseline mean (SD) age was 44.2 (11.7) years, HbA1c was 7.4% (0.9%) (57 [10] mmol/mol), 53% were women, and 51% used MDI. HCL TIR increased from (baseline) 55% (13%) to (26 weeks) 70% (10%) with the control group unchanged: (baseline) 55% (12%) and (26 weeks) 55% (13%) (difference 15% [95% CI 11, 19]; P < 0.0001). For HCL, HbA1c was lower (median [95% CI] difference -0.4% [-0.6, -0.2]; -4 mmol/mol [-7, -2]; P < 0.0001) and diabetes-specific positive well-being was higher (difference 1.2 [95% CI 0.4, 1.9]; P < 0.0048) without a deterioration in diabetes distress, perceived sleep quality, or cognition. Seventeen (9 device-related) versus 13 serious adverse events occurred in the HCL and control groups, respectively. CONCLUSIONS: In adults with type 1 diabetes, 26 weeks of HCL improved TIR, HbA1c, and their sense of satisfaction from managing their diabetes compared with those continuing with user-determined insulin dosing and self-monitoring of blood glucose. For most people living with type 1 diabetes globally, this trial demonstrates that HCL is feasible, acceptable, and advantageous.
引用
- McAuley SA, Lee MH, Paldus B, et al. Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial. Diabetes Care. 2020. PMID: 33055139. doi:10.2337/dc20-1447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。